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Background: ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of
organisation and actions that are necessary to give high-quality care to patients who have a speciﬁc type of
cancer. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers
give oncology teams, patients, policymakers and managers an overview of the elements needed in any healthcare
system to provide high quality of care throughout the patient journey. References are made to clinical guidelines
and other resources where appropriate, and the focus is on care in Europe.
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Oesophageal and gastric: essential requirements for quality care:
•
Oesophageal and gastric (OG) cancers are a challenging tumour group with a poor prognosis and wide variation in
outcomes among European countries. Increasing numbers of older people are contracting the diseases, and
treatments and care pathways are becoming more complex in both curative and palliative settings.
•
High-quality care can only be a carried out in specialised OG cancer units or centres which have both a core
multidisciplinary team and an extended team of allied professionals, and which are subject to quality and
audit procedures. Such units or centres are far from universal in all European countries.
•
It is essential that, to meet European aspirations for comprehensive cancer control, healthcare organisations
implement the essential requirements in this paper, paying particular attention to multidisciplinarity and
patient-centred pathways from diagnosis, to treatment, to survivorship.
Conclusion: Taken together, the information presented in this paper provides a comprehensive description of the
essential requirements for establishing a high-quality OG cancer service. The ERQCC expert group is aware that
it is not possible to propose a ‘one size ﬁts all’ system for all countries, but urges that access to multidisciplinary
units or centres must be guaranteed for all those with OG cancer.
1. Introduction: why we need quality frameworks
There has been a growing emphasis on driving up quality in cancer
organisations, given that there is wide agreement that much care is not
comprehensively accessible, not well coordinated and not based on cur-
rent evidence. This is the starting point of a report by the US Institute of
Medicine (IOM) in 2013 (Levit et al., 2013), which is blunt in describing a
‘crisis in cancer care delivery’, as the growing number of older people will
mean rising cancer incidence and numbers of survivors, while there are
pressures on workforces amid rising costs of care and complexity of
treatments. The European Cancer Concord (ECC), a partnership of pa-
tients, advocates and cancer professionals, has also recognised major dis-
parities in the quality of cancer management and in the degree of funding
in Europe, launching a European Cancer Patient’s Bill of Rights, a patient
charter that underpins equitable access to optimal cancer control, cancer
care and research for Europe’s citizens (Højgaard et al., 2016).
An assessment of the quality of cancer care in Europe was made as
part of the ﬁrst EU Joint Action on Cancer, the European Partnership for
Action Against Cancer (EPAAC, http://www.epaac.eu), which reported
in 2014 that there are important variations in service delivery between
and within countries, with repercussions in quality of care. Factors such
as waiting times and provision of optimal treatment can explain about a
third of the diﬀerences in cancer survival, while cancer plans, for ex-
ample, a national cancer plan that promotes clinical guidelines, pro-
fessional training and quality control measures, may be responsible for
a quarter of the survival diﬀerences.
The EU Joint Action on Cancer Control (CANCON), which replaced
EPAAC from 2014, also focused on quality of cancer care and in 2017
published the European Guide on Quality Improvement in Comprehensive
Cancer Control (Albreht et al., 2017). This recognises that many cancer
patients are treated in general hospitals and not in comprehensive
cancer centres (CCCs), and explores a model of ‘comprehensive cancer
care networks’ that could reconcile expertise in existing healthcare
systems given a lack of CCCs. Research also shows that multi-
disciplinary teams (MDTs) result in better clinical and organisational
outcomes for patients (Prades et al., 2015).
Countries have been concentrating expertise for certain tumour types in
such networks and in dedicated centres, or units, such as for childhood and
rare cancers, and most CCCs have teams for the main cancer types. For
common adult tumours, however, at the European level there has been
widespread eﬀort to establish universal, dedicated units only for breast
cancer, following several European declarations that set a target of the year
2016 for care of all women and men with breast cancer to be delivered in
specialist multidisciplinary centres. While this target has not been met
(Cardoso et al., 2017), the view of ECCO’s essential requirements expert
group is that the direction of travel is for all tumour types to adopt the
principles of such dedicated care.
All patients with oesophageal and gastric cancer must have access to
the care pathways and MDTs described in this document, and which are
subject to same approach to auditing, quality assurance and accred-
itation of a ‘unit’ that is emerging in breast cancer and other common
cancers such as colorectal.
2. Oesophageal and gastric (OG) cancer: key facts and challenges
2.1. Key facts
2.1.1. What are OG cancers?
• Cancers of the oesophagus (food pipe) and the stomach (gastric) are
grouped together because of common treatment and care features. In
the oesophagus there are two main types: squamous cell carcinoma
(SCC) and adenocarcinoma (AdC). In the stomach, the major type of
cancer is AdC, either diﬀuse or intestinal. There are also tumours that
straddle the oesophagogastric junction (OGJ), which are mostly AdCs.
The molecular proﬁles of oesophageal and gastric tumours have been
characterised: in the oesophagus, the molecular proﬁle of SCC is distinct
from that of distal oesophageal AdC, and the latter is similar to AdCs of
the OGJ (Cancer Genome Atlas Research Network, 2017). For gastric
cancer, 4 molecular subtypes have been identiﬁed (Cancer Genome
Atlas Research Network, 2014). (Not included in this OG cancer group
are less common carcinoma variants that aﬀect the oesophagus and the
stomach, mesenchymal tumours such as gastrointestinal stromal tu-
mours (GIST), neuroendocrine neoplasms, and lymphomas.)
• Epidemiological studies tend to divide OG cancers into simply the
oesophagus and gastric.
2.1.2. Incidence and survival
Oesophageal cancer is the 19th most common cancer in Europe.
Incidence in Europe was approximately 46,000 in the year 2012 (34,500 in
27 European Union countries), and there were approximately 39,500 deaths
(30,000, EU), and the 5 year survival number (prevalence) was approxi-
mately 47,000 (38,000, EU) (Ferlay et al., 2013). It is rare in young people.
There were wide diﬀerences in incidence and mortality among countries,
with Western European countries including the UK, Netherlands, Ireland
and Belgium with the highest rates, and the lowest in countries including
Macedonia, Greece and Cyprus. European men have a much higher in-
cidence of oesophageal cancer than women – about 4:1, although for
junctional tumours that arise in the stomach the ratio is lower. AdC has
increased greatly in incidence in the past few decades in developed coun-
tries – and has been among themost rapidly increasing of all cancers –while
SCC rates have remained stable (SCC is by far the more common type in
developing countries). More recently the incidence of AdC has tended to
stabilise, and mortality rates in the EU of men have been declining.
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Gastric cancer is the 5th most common cancer worldwide and the
7th most common in Europe. Incidence in Europe was about 140,000 in
the year 2012 (81,000 in 27 European Union countries), and there were
about 107,000 deaths (58,000, EU), and the 5 year survival number
(prevalence) was about 193,000 (118,000, EU) (Ferlay et al., 2013).
Patterns of incidence and mortality are very diﬀerent in Europe to oe-
sophageal cancer – Eastern European countries including Albania, Be-
larus, Macedonia and Russia have the highest rates, while Western
European countries, including Sweden, Switzerland, France, Norway
and the UK the lowest. More men than women have gastric cancer.
Generally, incidence of non-cardia gastric cancers has fallen, but cardia
cancers have increased in incidence. By far the most common form of
gastric cancer is AdC.
The EUROCARE study (1999–2007) reported a mean 5 year survival
for oesophageal cancer of 12.4% and an overall 5 year survival for
gastric cancer of 25.1% (Anderson et al., 2015). The authors report that
of the European regions, oesophageal cancer patients in Central Europe,
particularly Belgium, had the best survival while the poorest were in
Eastern Europe. For gastric cancer, Southern Europe had the best sur-
vival; Ireland and the UK, and Eastern Europe, the lowest.
2.1.3. Aetiology and risk factors
• Male gender and older age are risk factors for OG cancers. Smoking and
alcohol play an important role for oesophageal cancer, and poor diet
(including high salt intake) for gastric cancer. Obesity is particularly
associated with a rising incidence of junctional cancers (with current
research investigating obesity types and gender diﬀerences).
Carcinogens are risk factors for gastric cancer in some occupations.
• The most important associated conditions for oesophageal cancer
are gastro-oesophageal reﬂux disease (GORD) and Barrett’s oeso-
phagus, a premalignant condition for oesophageal AdC; and for
gastric cancer, Helicobacter pylori infection (which the International
Agency for Cancer Research identiﬁes as a carcinogen for gastric
cancer), and Epstein Barr virus.
• There is limited evidence for inherited links with oesophageal
cancer, including familial clusters of Barrett’s oesophagus and oe-
sophageal AdC, and the association in the rare condition tylosis
(hyperkeratosis palmaris et plantaris) with a high lifetime risk of
SCC development. In gastric cancer there is familial clustering in
5–10% of cases (probably due to the interplay between genetic
susceptibility and environmental factors such as H. pylori infection
and diet), and 1%–3% are hereditary. Hereditary diﬀuse gastric
cancer (HDGC), an autosomal-dominant cancer-susceptibility syn-
drome that aﬀects the stomach, is mostly caused by germline mu-
tations in the gene encoding E-cadherin (CDH1), leading to the oc-
currence of diﬀuse gastric cancer in young people (Guilford et al.,
1998). Gastric cancer can also develop in the setting of other her-
editary cancer syndromes (such as Lynch syndrome).
2.1.4. Prevention and screening
• At present, education about risk factors such as smoking, diet and
obesity is the only primary prevention tool. Secondary prevention
could include identifying and treating pre-cancerous conditions,
such as Barrett’s oesophagus, and H. pylori, but this is a complex
area (H. pylori, for example, may be associated with lower incidence
of oesophageal cancer). Chemoprevention, including taking aspirin,
is among the interventions currently being studied.
• Screening is carried out for gastric cancer in Japan and South Korea,
as there is high incidence in these countries (it is the most frequent
cancer in Japan). There are no population level screening pro-
grammes elsewhere, but there are some guidelines to screen in-
dividuals who may be at higher risk (Yoon and Kim, 2015; Dinis-
Ribeiro et al., 2012a).
2.1.5. Diagnosis and staging
• Symptoms that lead to a diagnosis of oesophageal cancer include
diﬃculty in swallowing (dysphagia), lack of energy and strength
(asthenia), gastrointestinal bleeding, weight loss, vomiting, in-
digestion, heart burn and chest pain. Common gastric cancer
symptoms include dysphagia, asthenia, indigestion, vomiting,
weight loss, early satisfaction of appetite and anaemia.
• Diagnosis of OG cancers is usually made from samples of the mucosa
obtained by endoscopy and analysis by an experienced pathologist.
High-quality staging is essential to determine optimal treatment,
and includes endoscopic ultrasound to determine the extent and
location of tumours, particularly of the oesophagus. Cross-sectional
imaging with CT is used for detection of lymph node involvement
and distant metastases. PET/CT is indicated in staging of oesopha-
geal cancer and for some gastric cancers with increased sensitivity
for distant metastases. Laparoscopy can additionally detect small
volume peritoneal disease beyond the resolution of CT or PET/CT
for both OG junctional and gastric cancers.
• The clinical and pathological staging of oesophageal, junctional and
gastric cancers is determined by the TNM, 8th Edition. According to
this classiﬁcation, cancers crossing the OGJ and with their epicentre
in the proximal 2 cm of the stomach are staged as oesophageal
cancers. Cancers whose epicentre is more than 2 cm distal from the
OGJ (in the proximal 2–5 cm of the stomach) are staged as gastric
cancers even if the OGJ is involved. All tumours in the stomach that
do not cross the OGJ are classiﬁed as gastric cancers (American
Joint Committee on Cancer, 2016).
2.1.6. Treatment
• Endoscopic therapy, including mucosal resection/submucosal dis-
section, is the preferred surgical approach in both very early, su-
perﬁcial oesophageal and gastric cancers (T1a). Surgical resection is
carried out for early stage cancers not suitable for endoscopic re-
section and can be curative. Radical and often complex surgical
techniques, including lymph node procedures, are carried out in
more advanced, operable OG cancers, together with various perio-
perative chemotherapy and chemoradiotherapy regimens. Not all
patients are willing or able to undergo surgery because of co-mor-
bidity but can still receive chemoradiotherapy or radiotherapy.
• In advanced/metastatic inoperable oesophageal cancer, care com-
prises palliative chemotherapy, and radiotherapy in some cases. In
advanced/metastatic inoperable gastric cancer, standard treatment
is chemotherapy. Trastuzumab is mandatory for HER2 positive
gastric cancer (which is 10%–15% of cases) and an anti-VEGFR-2
monoclonal antibody (ramucirumab) can be considered for second
line alone or with chemotherapy. Immunotherapy checkpoint in-
hibitors (PD-1/PD-L1, CTLA4) have also shown eﬃcacy in early
studies in advanced OG cancer. Nutritional support and palliative
care should be considered from the beginning of the treatment for
all patients.
2.2. Challenges in care of OG cancers
2.2.1. Inequalities
• Eastern Europe has the worst survival for OG cancers, in line with
most tumour types, which is a major concern. But there also appear
to be substantial variations in survival among Western European
countries – for oesophageal cancer, the 5 year relative survival rate
was 8.9% in Denmark and 16.2% in Germany; for gastric cancer
16% in Denmark and 32.4% in Italy (ﬁgures from EUROCARE-5,
1999–2007) (De Angelis et al., 2014). The reasons could lie in a
number of factors, such as use of multimodal therapies, surgical
approach and post-operative care, but a lack of comprehensive data
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from cancer registries is also likely to be a current challenge parti-
cularly for data on epidemiology and stage at presentation
(Messager et al., 2016a).
• A majority of cases are among older people – for example, in the UK
56% of cases at diagnosis are in those over 70. There is evidence that
older cancer patients are undertreated (Quaglia et al., 2009) and are
also underrepresented in clinical trials (Scher and Hurria, 2012).
Providing the standard of care to older people in all cancers is im-
portant and is particularly challenging in these cancers, because of
the numbers of patients frequently with several comorbidities to
manage, and consistent partnership with geriatric specialists can be
needed.
2.2.2. Diagnosis and staging
• Treatment of symptoms that appear to be common complaints such
as dyspepsia can delay diagnosis. Many patients with OG cancers are
diagnosed when their disease is at an advanced stage, owing to this
vagueness of, or even lack of, symptoms, and lack of understanding
symptoms and their relevance to possible underlying cancer.
Overall, about 60% of people with OG cancers are not eligible for
curative treatment owing to late presentation or co-morbidities.
Raising public awareness of symptoms including persistent heart-
burn and dysphagia may be eﬀective, such as with the UK Be Clear
on OG Cancer campaign in which TV and ‘roadshows’ targeted men
and women over 50 from lower socioeconomic groups, encouraging
them to visit their GP (http://www.cancerresearchuk.org/health-
professional/awareness-and-prevention/be-clear-on-cancer/
oesophago-gastric-cancers-campaign). The brieﬁngs and campaign
materials are on the site. A supporting study also showed wide variation
in referral rates by GPs for gastroscopy and a higher risk of poorer
outcomes among those with lower rates (Shawihdi et al., 2014).
• OG cancers are particularly complex to stage and assess for treat-
ment, and there are variations in investigations and referral strate-
gies among European countries that can aﬀect outcomes.
2.2.3. Treatment
• Centralised multidisciplinary expertise is essential to determine the
best holistic treatment course and to implement the latest research
ﬁndings. Fragmentation in services and expertise, still apparent in
many countries, must be eliminated.
• Treatment of OG cancer with curative intent has been clearly shown
to have a volume-outcome eﬀect, so centres must have a suﬃcient
number of cases to ensure and maintain expertise.
• OG cancer treatment includes surgical options that are highly de-
manding and must be carried out in specialised centres with ex-
perienced surgeons and anaesthesiologists. These centres should
include emergency presentations. Decision making about treatment
often involves a complex assessment of the balance between beneﬁts
and complications, not least the decision about whether to carry out
curative or palliative care.
• Surgeons undertaking operations for OG cancers should treat all
types – oesophageal, junctional and gastric – as there are common
principles to ensure development and maintenance of expertise.
• Specialist care during and after surgical treatment is critical to re-
ducing post-operative mortality.
• Assessment of and support for nutritional status is needed for all
patients as many patients are malnourished.
• Low numbers of operable cases means that the concept of a ‘high
volume’ surgical centre can involve far fewer cases than more
common operable cancers, such as colorectal. Inoperable cases,
however, also require specialist interventions and treatment. It is a
challenge for health services to consistently provide a full multi-
disciplinary team for all cases.
• Overall, patient care pathways for OG cancers are among the most
complex to organise and manage, given the need for high quality
local diagnostic and palliative care services and their integration
with specialist centres.
2.2.4. Palliative treatment and supportive care
• It is essential that patients not undergoing curative treatment re-
ceive palliative and supportive care as part of their multidisciplinary
treatment. Palliative care is often lacking in multidisciplinary teams
but essential to quality of life.
• Patient reported outcomes and quality of life are crucial in OG
cancers but are often poorly addressed, particularly in clinical trials.
• The number of cancer survivors is rising, and some survivors suﬀer
for many years from ongoing conditions, such as digestive disorders,
that result from the primary treatment of their cancer. Specialist
supportive care for a growing population of survivors is becoming a
major issue.
2.2.5. Clinical research
The main challenges in clinical research for OG cancers in Europe
are the relative low incidence compared with Asia, variability in mul-
tidisciplinary management and treatment, and lack of centralisation of
cancer care, which all contribute to the limited access for many patients
to clinical trials. Practice-changing research for OG cancer has been
conducted through strong national groups, but conducting international
clinical trials remains a challenge. Close collaboration among surgeons,
oncologists, pathologists and biologists is needed to generate innovative
translational research that will direct better clinical trials.
2.2.6. Patient advocacy
OG cancers do not yet have many national patient groups. They can
play a vital role in service improvement strategies, in providing in-
formation, and in the quality of life of patients, and require support and
funding.
3. Organisation of care
Essential requirements for the organisation of OG cancer care en-
compass:
• Cancer care pathways
• Timelines of care
• Minimum case volumes
• Multidisciplinary teamworking among core and extended groups of
professionals, in a dedicated centre or unit
• Audit, performance measurement, quality assurance of outcomes
and care
• Professional education, enrolment in clinical trials and delivery of
patient information.
These topics are outlined in the following sections, with reference to
national and European resources and clinical guidelines, where ap-
propriate.
3.1. Care pathways and timelines
• Care for OG cancer patients must be organised in care pathways that
chart the patient’s journey from their perspective rather than that of
the healthcare system. The European Pathway Association deﬁnes a
care pathway as “a complex intervention for the mutual decision
making and organisation of care processes for a well-deﬁned group
of patients during a well-deﬁned period”. This broad deﬁnition
covers terms such as clinical, critical, integrated and patient path-
ways that are also often used. See http://e-p-a.org/care-pathways.
• Pathways should incorporate current evidence set out in national
and European guidelines. An example of a pathway for OG cancers is
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from the Cancer Council, Victoria, Australia (Cancer Council
Victoria, 2018).
• Primary care practitioners are the usual referrers of those with
suspected OG cancers and need timely access to hospital specialists.
In England and Wales, the maximum time for an appointment to
check suspected symptoms of all cancers is 2 weeks (NICE guidance,
UK). Other countries have shorter targets: in the Netherlands, the
maximum time for an appointment when a malignancy is suspected
is 1 week. The ERQCC expert group strongly recommends that
countries ensure that waiting times are below these times, as is the
case in several European countries that make urgent referrals within
48 h. There must be documented local referral policies for diagnosis
of OG cancers, agreed between all levels of service including pri-
mary care.
• Times to report a diagnosis of OG cancer and the opportunity to start
treatment are crucial to the wellbeing of patients to avoid as much
anxiety as possible. Guidelines in the Netherlands (and similarly in
Germany), for example, state that the maximum time for diagnostic
and staging procedures is 3 weeks, and the maximum time from ﬁrst
appointment to ﬁrst treatment is 6 weeks.
• Treatment planning for all patients with OG cancer must be un-
dertaken by a multidisciplinary team (see below).
• After a diagnosis, it must be clear to the patient which professional
is responsible for each step in their multidisciplinary treatment
pathways and who is following the patient during the journey
(usually called a case manager or patient navigator). In many
countries, case managers during the main stages of treatment are
cancer nurses (European Partnership for Action Against Cancer,
2018), with some being specialists in OG cancers. There must also be
a medical professional responsible for coordinating treatment mod-
alities and specialties. This is usually a surgeon or medical/clinical
oncologist, depending on local agreements and the stage of the disease.
• Some patients with OG cancers present as emergencies. While it is
preferable for these patients to be treated by the OG team from the
start, this is often not possible. Care must be transferred to the OG
team straight after the emergency procedure. In the UK, the survival
rate at 1 year for emergency admissions is only about half that of
other routes to diagnosis (Coupland et al., 2007).
• Rehabilitation and survivorship are major issues in OG cancers.
Regular follow-up may detect recurrence, though there is no evi-
dence that it improves survival outcomes (National Institute for
Health and Care Excellence, 2018; Baiocchi et al., 2016). However,
OG cancer treatments, both acutely and in the longer term, create
signiﬁcant symptoms which impair quality of life. Patients with OG
cancer are living longer and these treatment related side-eﬀects can
be lifelong. It is therefore essential for units and centres undertaking
OG cancer treatment to ensure there is an easily accessible multi-
disciplinary service to manage these problems.
3.2. OG centres/units: requirements
• It is essential for all patients to be treated in a multidisciplinary
centre; that members of the multidisciplinary team see a certain
annual number of cases; and that members of the core team dedicate
signiﬁcant time to treating patients with OG cancer, although re-
quirements vary according to the various disciplines in the team.
There is good evidence that countries that have centralised OG
cancer services and/or specify a minimum number of cases achieve
better outcomes, especially in post-operative mortality (Glatz and
Höppner, 2017). One study, looking at data on oesophageal surgery
in Sweden, found that a surgeon’s volume, rather than hospital
volume, is the key variable (Derogar et al., 2013). In gastric surgery,
guidelines and studies show that the D2 lymphadenectomy proce-
dure should be carried out only in high volume centres (Smyth et al.,
2016; Songun et al., 2010).
• Supporting evidence for guidance from NICE notes that there has
been a recommendation in the UK NHS for the minimum size of
catchment population for a specialist OG centre to be 1 million, and
adds that units now tend to cover populations of 2 million or more,
following centralisation initiatives. NICE also says it is diﬃcult to
assess surgeon volume given a requirement for round the clock
specialist surgeon cover and operations increasingly being carried
out by two consultants. The draft guidance lists studies on organi-
sation of surgical services and hospital volume, although most are of
low or moderate quality (National Institute for Health and Care
Excellence, 2018). The Association of Upper Gastrointestinal Sur-
geons of Great Britain and Ireland has said that an ideal OG unit
would consist of 4–6 surgeons each carrying out a minimum of
15–20 OG resections a year serving a population of 1–2 million
(Association of Upper Gastrointestinal Surgeons of Great Britain and
Ireland, 2010). The German Cancer Society requires 30 gastric re-
sections per year by two dedicated surgeons to qualify for certiﬁ-
cation as a gastric cancer centre (German Cancer Society, 2016).
• Based on the existing evidence, the ERQCC expert group re-
commends that a specialist multidisciplinary team at a centre or
network should manage and consult on about 200 new OG cases
each year (the total being both curative and palliative treatments,
and those referred but treated elsewhere) although it is recognised
that in some countries both incidence and geography can inﬂuence
case volume and a lower total would be more appropriate.
• All OG units must have a follow-up programme in place in ac-
cordance with guidelines.
3.3. The multidisciplinary team
Treatment strategies for all patients must be decided on, planned
and delivered as a result of consensus among a core multidisciplinary
team (MDT) that comprises the most appropriate members for the
particular diagnosis and stage of cancer, patient characteristics and
preferences, and with input from the extended community of profes-
sionals. The heart of this decision making process is normally a weekly
or more frequent MDT meeting where patients are discussed with the
objective of balancing the recommendations of clinical guidelines with
the ‘reality’ of the individual patient. Currently, there is variability in
OG MDTs across Europe both in the constitution of the teams and the
frequency of meetings (Messager et al., 2016a).
The standard of care for patients with OG cancer includes a core
MDT of dedicated health professionals from the following disciplines:
• Gastroenterology/endoscopy
• Pathology
• Radiology/interventional radiology
• Surgery
• Nuclear medicine
• Radiation oncology
• Medical oncology
• Nursing
• Nutrition
• Palliative care.
This core MDT must discuss:
• All new patients after diagnosis and staging to decide on an optimal
treatment plan whether for curative or palliative intent
• Patients after major treatment to decide on further treatment (such
as adjuvant chemotherapy) and follow-up
• Patients with a recurrence during follow-up to decide on optimal
treatment
• Patients for whom changes to treatment programmes are indicated
and have multidisciplinary relevance and/or may require deviations
from clinical practice guidelines.
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Healthcare professionals from the following disciplines comprise the
extended MDT. They do not need to attend every MDT meeting but
have essential roles for aspects of patient care and their expertise must
be included when necessary:
• Anaesthesia/intensive care
• Geriatric oncology
• Oncology pharmacy
• Psycho-oncology
• Physiotherapy
• Rehabilitation and survivorship.
Guidelines from ESMO emphasise that nutritional counselling is
essential for localised and advanced cases; that specialised supportive
and palliative care is available for advanced cases; and survivors have
access to gastrointestinal specialists throughout their follow-up (Smyth
et al., 2016). To ensure timely and adequate preoperative workup and
preparation, anaesthesia/intensive care should be involved as soon as
possible after the decision for surgical treatment.
3.4. Disciplines within the core MDT
3.4.1. Gastroenterology/endoscopy
Gastroenterologists are usually the ﬁrst physicians who assess a
patient with possible OG cancer. In some countries gastroenterologists
also carry out medical oncology treatments.
Upper gastrointestinal endoscopy is the principal investigation, with
biopsy for histological conﬁrmation of diagnosis of OG cancer.
Endoscopy is carried out by gastroenterologists, surgeons, nurse en-
doscopists and radiologists, depending on country/locality.
Endoscopic diagnosis can be supplemented by endoscopic ultra-
sound as part of interventional staging.
Interventional endoscopy is also part of the management of patients
with OG cancer. In early stage disease, endoscopic resection is per-
formed (endoscopic mucosal resection, EMR; endoscopic submucosal
dissection, ESD). This may be supplemented by endoscopic-directed
mucosal ablation techniques such as radiofrequency ablation.
Endoscopic techniques also have a role in symptomatic palliation in-
cluding stent placement or laser therapy for stenosing cancers.
Essential requirements
• A gastroenterologist/endoscopist must be trained and accredited in
diagnostic upper GI endoscopy (Beg et al., 2017; Bisschops et al.,
2016; Dinis-Ribeiro et al., 2012b; Weusten et al., 2017; Spaander
et al., 2016). Endoscopists performing interventional endoscopy and
endoscopic ultrasound must have a suﬃcient practice as speciﬁed by
country regulations (e.g., according to number of procedures such as
EMR/ESD performed a year, completeness of procedures, FNA/core
needle biopsies).
• High-deﬁnition video endoscopy must be used for diagnosis and
treatment.
• Facilities for endoscopic palliation of malignant dysphagia must be
available within 24 h of presentation.
• The endoscopy service must be subject to quality assurance with
appropriate regular audit.
• In countries where systemic treatment of gastrointestinal cancer is
carried out by gastroenterologists, they must have a qualiﬁcation
and expertise in the systemic treatment of gastric cancer and the
management of side-eﬀects (e.g. as demonstrated by a certain
number of chemotherapeutic cycles and targeted agents given each
year). They must also follow up after surgery to make sure that
adjuvant treatment, for example, is applied when indicated.
3.4.2. Pathology
Pathology, including molecular pathology, is playing an
increasingly critical role in the diagnosis of OG cancer. The role of the
pathologist is to conduct a detailed study of the tumour based on the
sample/specimen received for analysis and to prepare a pathology re-
port for discussion at the MDT.
Essential requirements
• Pathologists must have expertise in reporting on OG cancer pre-
operative biopsies, EMR/ESD specimens and surgical specimens. They
must know recently published guidelines and reviews on pathological
reporting and their reports must contain a list of items as recommended
by professional organisations and internationally recognised classiﬁca-
tions used for histopathological diagnosis (Bosman et al., 2010; Lauren,
1965). The use of structured (or synoptic) reports is strongly en-
couraged; see examples from the Royal College of Pathology in the UK
(Royal Society of Pathologists, 2007a, 2007b).
• Second opinion must be sought internally for diﬀerential diagnosis
between precursor lesions (dysplasia) and invasive cancer; dis-
crepancy between the clinical and pathological diagnosis; and for
rare tumours in which pathologists have little experience (such as
early intra-epithelial lesions of HDGC). External second opinion
must be made to national or international experts in certain cases.
• With the increasing importance of molecular data in therapeutic
decisions (Baraniskin et al., 2017), access to an accredited molecular
pathology laboratory must be guaranteed, although it may not be on
site. For OG adenocarcinomas the evaluation of HER2 status is part
of standard diagnostics; MSI is recommended only for stage IV. PD-
L1 expression and detection of EBV in tissue (EBER) are not re-
commended yet in routine use. Search for CDH1 mutations is
mandatory for HDGC (van der Post et al., 2015).
3.4.3. Radiology/interventional radiology
OG cancers are complex diseases that require multimodal imaging
to assess and stage. Imaging the oesophagus and stomach is challenging
because they are ﬂexible tube/hollow organs, not optimally distensible
and surrounded by other vital organs. Conventional radiography and
barium swallow with ﬂuoroscopy is not indicated as part of the as-
sessment of OG cancer. Multidetector CT (MDCT) is the modality of
choice to assess stage (Ba-Ssalamah et al., 2009, 2003, 2011). MRI is
not routinely used in the preoperative evaluation of these cancers, but is
useful in the diagnostic work up of liver lesions.
Interventional radiology can be required for diagnosis, particularly
of recurrent disease, and therapy in OG cancer, particularly in the
management of postoperative complications and relief of symptoms in
recurrent disease (Tamandl et al., 2016a, 2016c, 2016b).
Essential requirements
• Radiologists must have expertise in gastrointestinal imaging.
• OG cancer staging is based mainly on computed tomography (CT)
ﬁndings, and radiologists must have knowledge of CT protocols for
assessment of primary tumours, nodal spread, intraperitoneal dis-
ease and metastatic spread.
• Radiologists must also know how to assess response after neoadju-
vant cancer therapy. This is an evolving area where integration of
radiologic, clinical and endoscopic data is mandatory.
• Radiologists must know when to refer a patient to nuclear medicine
for PET/CT. State-of-the-art CT, liver MR imaging and PET/CT, in-
cluding adequate reporting, must be available.
• Interventional radiologists must be competent in image guided
biopsy techniques and therapeutic interventions such as stent pla-
cement and have competence in intravascular techniques (or be able
to refer to a colleague).
3.4.4. Nuclear medicine
Nuclear medicine plays a role in the management of oesophageal
and OGJ cancer patients, and in some gastric cancer patients (Boellaard
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et al., 2015; Jadvar et al., 2017).
There is evidence of the eﬃcacy of 18F FDG PET/CT in selected
clinical indications:
• Initial staging of oesophageal cancer, stages IB to IIIC: based on
ESMO guidelines, 18F FDG PET/CT should be carried out in patients
who are candidates for oesophagectomy (Lordick et al., 2016).
Evidence shows 18F FDG PET/CT has a high accuracy for N and M
staging, especially in identifying otherwise undetected distant me-
tastases, and so is key in decision-making (i.e. ﬁnding distant me-
tastases may prevent patients from undergoing futile surgery)
• Prediction of response: based on ESMO guidelines, tumour response to
chemotherapy may be predicted early in oesophageal and OGJ AdC
• Prognostic value, both at initial diagnosis and during early response
monitoring
• Early detection of relapse, in patients with increased tumour mar-
kers and/or inconclusive CT or MR.
Other clinical situations with limited evidence, but with ongoing
research and promising preliminary results are:
• Radiation oncology treatment planning, deﬁning the gross tumour
volume (GTV) and evaluating candidates with probable oligometa-
static disease before stereotactic body radiotherapy (SBRT)
• Guiding biopsies with the information supplied by 18F FDG PET/CT,
improving the probability of successful extraction of diagnostic tissue.
The role of the nuclear medicine physician is to oversee all aspects
of PET/CT for patients who require this procedure, including indica-
tions, multidisciplinary algorithms and management protocols.
Essential requirements
• PET/CT and SPECT/CT must be available and must be managed by
nuclear medicine physicians with the appropriate expertise.
• Nuclear medicine must be able to perform daily veriﬁcation proto-
cols and to react accordingly. Quality-assurance protocols must be in
place. An option for ensuring the high quality of PET/CT scanners is
provided by the European Association of Nuclear medicine (EANM)
through EARL accreditation.
3.4.5. Surgery
Surgery is a component of curative treatment of OG cancer in about
25% of patients (NHS, 2016). The majority of these patients require
multidisciplinary treatment usually combining surgery and periopera-
tive chemotherapy or preoperative chemoradiotherapy, although sur-
gery only is appropriate for selected patients with early stage disease
not suitable for endoscopic therapies (Allum et al., 2011). Surgery also
has a role in the palliative setting to relieve local symptoms that cannot
be treated endoscopically.
The role of the surgeon is to assess suitability for surgery in terms of the
extent of the cancer, including laparoscopy for staging, and also patient
ﬁtness in the context of the multidisciplinary decision; undertake the sur-
gical procedure; and be responsible for perioperative care. Minimally in-
vasive techniques are becoming part of standard practice and should be
introduced following structured and proctored training of the surgical team.
Essential requirements
• Staging laparoscopy must be undertaken by a specialist surgeon who
regularly performs OG cancer surgery.
• OG resection surgery must only be carried out in specialist centres
by teams of appropriately trained surgeons with audited outcomes.
There must be at least two experienced surgeons per unit who
dedicate a signiﬁcant amount of their time to OG cancer. The
ERQCC expert group recommends that surgeons should perform
both oesophageal and gastric resections. Centres must have
suﬃcient numbers to ensure maintenance of expertise.
• OG surgeons at a specialist centre must provide a 24/7 on-call ser-
vice including emergency service and advice to local hospitals for
malignant OG disease as well as spontaneous and iatrogenic per-
foration, including benign pathology.
• Surgeons must ensure that perioperative care for patients under-
going OG resection are provided by specialist teams of nurses (both
in the operating theatre and on the wards) and anaesthetists/in-
tensivists with access to intensive and critical care facilities.
3.4.6. Radiation oncology
Radiotherapy is often used before surgery in oesophageal cancer to
facilitate curative resection with clear margins and to reduce the risk of
local recurrence, in particular in SCC. Preoperative chemoradiation in oe-
sophageal cancer has been shown to increase disease free and overall
survival. It can be selectively used after surgery in a small minority of
patients with high risk factors for local recurrence who did not receive pre-
operative radiotherapy. SCC of the oesophagus can also be treated with
chemoradiation alone without surgery. Decision-making is multi-
disciplinary and takes many factors into account (Lordick et al., 2016).
The role of radiotherapy in the treatment of gastric cancer is under
study (Smyth et al., 2016).
The role of the radiation oncologist is to determine the volume to be
irradiated based on the clinical staging of the primary tumour. Multimodal
imaging including a CT in the treatment position is used to delineate the
target volume. Radiation oncologists are responsible for the dose fractio-
nation prescription in keeping with national and international guidelines.
Radio(chemo)therapy can help control AdCs in people who are not
healthy enough for surgery or to ease (palliate) symptoms in people
with advanced cancer that has caused severe dysphagia, bleeding or
pain. Radiation oncologists are responsible for patients’ ongoing care
and wellbeing according to these clinical situations.
Essential requirements
• Access to radiotherapy must be provided in the centre.
• The radiotherapy centre must have agreed protocols for radio-
therapy and concurrent chemoradiotherapy for OG cancer based on
international guidelines. The image guidance policy and quality
assurance guidelines must be clearly described and documented.
External quality assurance audits are highly recommended.
• Access to 3D conformal radiotherapy and intensity modulated radiation
therapy (IMRT), where clinically indicated, must be available and de-
livered according to clearly deﬁned protocols. Radiation oncologists
must be responsible for follow-up and management of late toxicity and
survivorship issues. Protocols must be in place for the management of
late toxicity including digestive, pulmonary and cardiac problems.
3.4.7. Medical oncology
Medical oncology plays an important role in the management of OG
cancer patients, and speciﬁcally of patients with locally advanced and
metastatic disease (stages IB–IV). In these situations, the medical oncologist
is the lead oncology specialist. The role of the medical oncologist is to:
• Coordinate all aspects of multimodal drug treatment, which may
include coordination of clinical and molecular diagnostics, and in-
dication setting and distribution of treatment with systemic thera-
pies (such as perioperative, adjuvant and palliative chemotherapy,
monoclonal antibodies, and, potentially in the future, signal-trans-
duction inhibitors and immunotherapies)
• Initiate and coordinate symptom-related management in coopera-
tion with specialists who manage tumour or disease-related symp-
toms (palliative and symptomatic treatment, including nutritional
support), and rehabilitation and survivorship
• Play a lead position in clinical trial design for locally advanced and
metastatic OG cancers.
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Essential requirements
• Medical oncologists treating OG cancer must have in-depth under-
standing of the prognostic and predictive clinical and molecular
factors that contribute to indication setting, treatment intensity and
duration of drug therapies. These factors must be considered with
clinical goals and other, non-disease related factors and patient
preferences. Medical oncology for OG cancer is increasingly com-
plex, as evidenced in the latest clinical guidelines and reports
(Lordick et al., 2016; Smyth et al., 2016, 2017; Ajani et al., 2017).
• Medical oncologists must have in-depth knowledge of the interac-
tion of cancer-speciﬁc treatments with other conditions (such as
comorbidities and their management). This includes supportive
treatment for management of pain, weight loss, gastrointestinal
symptoms and side-eﬀects of systemic therapy.
3.4.8. Nutrition/diet
Nutritional and metabolic problems are frequent in patients with
OG cancer; aggressive curative surgery and perioperative multimodal
oncologic care can induce a progressive nutritional decline. Indications
for nutritional therapy are prevention or treatment of malnutrition and
catabolism. Nutrition therapy may be indicated even in patients
without obvious disease-related undernutrition, if it is anticipated that
the patient will be unable to eat or cannot maintain appropriate oral
intake for a long period perioperatively. In this case, the surgeon should
place a naso-jejunal tube or needle catheter jejunostomy in-
traoperatively. Diets supplemented with speciﬁc nutrients can be used
perioperatively to reduce the inﬂammatory response and to enhance
the immune function.
Physical activity is associated with improvement of aerobic capa-
city, increasing anabolism and muscle strength, enhancing health-re-
lated quality of life, and anxiety reduction.
The nutritionist or dietitian is an essential member of the core MDT
to manage these interventions, as set out in guidelines (Weimann et al.,
2017; Arends et al., 2017).
Essential requirements
• Nutritionists must carry out systematic nutrition risk screening at
the time of diagnosis of OG cancer, including assessment of body
composition (fat free mass, visceral fat), dietary intake and physical
activity.
• Nutritionists must prepare a nutrition intervention plan (in case of
inadequate food intake, oral nutritional supplements, enteral or
parenteral nutrition should be used)
• Nutritionists must support the tolerability of therapeutic measures.
• Counselling with good communication skills is necessary to ensure
compliance with plans.
• Regular follow-up of body weight and BMI must be carried out.
3.4.9. Nursing
The OG pathway is complex and nurses are in a key position to
identify and address the holistic needs of the individual from diagnosis
through to recovery. Through strategies such as tailored support, timely
information and symptom management nurses can alleviate distress
and promote supported self-management.
Nurses can refer patients to services such as patient support groups,
clinical psychology and welfare advisors to ensure the patient’s needs
are optimised and addressed.
Extended nursing roles for cancer nurses (known for example as
clinical nurse specialists or advanced nurse practitioners) are now
common in some countries and include performing endoscopy, deli-
vering systemic treatments and running survivorship clinics (NHS
National Cancer Action Team, 2010; Royal College of Nursing, 2009).
See also the Recognising European Cancer Nursing (RECaN) project
(http://www.ecco-org.eu/Policy/RECaN).
Essential requirements
• Nurses working in OG centres must have insight into each patient’s
experience of their disease, treatment and side-eﬀects, and must
promote a culture of shared decision-making and patient involve-
ment throughout the cancer continuum (from diagnosis through to
recovery). They must act in the best interest of the patient and those
important to them to help coordinate diagnosis, treatment and
aftercare, acting as a key worker (or case manager) where appro-
priate. In some circumstances it may be more appropriate for the
palliative care nurse to assume this role but at all times the patient
should have clarity on who their single point of contact is.
• Nurses must focus on the timely, holistic assessment and manage-
ment of the patient and represent their needs at the MDT where
appropriate. Nurses must ensure systematic screening throughout
the disease trajectory to uncover physical symptoms such as pain,
psychosocial distress, impairment of physical functioning, mal-
nutrition and frailty.
• Nurses must be trained in perioperative care for patients undergoing
all forms of OG surgery and procedures.
• In collaboration with the MDT, nurses must agree on the optimal
methods, frequency and duration of follow-up for people following
treatment for OG cancer.
3.4.10. Palliative care
About 60% of patients with OG cancer have incurable disease and
need palliative care in conjunction with cancer treatments to manage
distressing clinical complications and symptoms, and improve their
quality of life and that of their families (Temel et al., 2010; Hui et al.,
2015; Quill and Abernethy, 2013). Palliative care, as deﬁned by the
World Health Organization, applies not only at end of life but
throughout cancer care (http://www.who.int/cancer/palliative/
deﬁnition).
All professionals working with OG cancer patients should have
knowledge of palliative care, but the ERQCC expert group considers that in
this patient group specialists must be integrated into the core team.
The role of the palliative specialist is to:
• Manage palliative care and make recommendations to other spe-
cialists about symptom control and other conditions
• Identify patients who need palliative care through the systematic
assessment of distressing physical, psychosocial and spiritual pro-
blems
• Treat disease and treatment-related symptoms and oﬀer psychoso-
cial and spiritual care
• Incorporate support for family members
• Provide early integrated palliative care in conjunction with cancer
speciﬁc treatments
• Provide end-of-life care and support decision making, working with
primary care palliative care providers (Gallais Sérézal et al., 2016).
Essential requirements
• All OG cancer patients with severe symptoms or suﬀering, or pa-
tients with metastatic or locally advanced disease, must be in-
troduced to a specialist palliative care team, irrespective of the
cancer-speciﬁc treatment plan.
• The palliative care team must include palliative care physicians and
specialist nurses, working with an extended team of social workers,
chaplains, psychotherapists, physiotherapists, occupational thera-
pists, dieticians, pain specialists and psycho-oncologists.
• The specialised palliative care team must have good knowledge of
cancer disease and cancer treatments including adverse eﬀects of
treatment, disorders of digestive physiology, cachexia and mal-
nutrition, and rehabilitation needs of patients, to be able to oﬀer
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holistic care in collaboration with other professionals.
• To ensure the continuity of care at home, the palliative care team
must work with primary care providers.
• Palliative care specialists and oncologists must aspire to meet the
standards of the ESMO Designated Centres of Integrated Oncology &
Palliative Care (http://www.esmo.org/Patients/Designated-
Centres-of-Integrated-Oncology-and-Palliative-Care).
3.5. Disciplines in the extended MDT
3.5.1. Anaesthesia/intensive care
Anaesthesiologists have key roles in the management of patients
with OG cancer. These include:
• Surgical risk assessment
• Preoperative optimisation of co-existing medical conditions
• Perioperative clinical pathway management (including in-
traoperative care)
• Postoperative management in intensive/critical care facilities
• Acute and chronic pain management.
Enhanced recovery pathway guidelines for oesophageal and gastric
surgery have been published and should be implemented to facilitate
perioperative care (Feldheiser et al., 2016).
Surgical centres must have the necessary anaesthetic and critical
care expertise and infrastructure not only to manage elective OG cancer
surgery but also to provide the often complex support for postoperative
complications in high-risk patients, which may include extended car-
diovascular support and invasive ventilator support (e.g. oscillating
ventilation and ECMO).
Essential requirements
• Patients undergoing OG cancer surgery must have appropriate pre-
operative assessment led by anaesthesiologists.
• Anaesthesiologists undertaking OG cancer surgery must have ade-
quate experience in thoracic surgery anaesthesia including one-lung
ventilation, the use of double-lumen endotracheal tubes and bron-
chial blockers and awake ﬁbre optic bronchoscope intubation; epi-
dural analgesia and thoracic-abdominal regional techniques; and
invasive intraoperative haemodynamic monitoring.
• Postoperative care must be undertaken in dedicated intensive/cri-
tical care facilities.
• The standard of care for OG cancer surgery includes enhanced re-
covery programmes, which are recommended for all OG centres.
• Pain control services led by anaesthesiologists must be available in
centres providing care for patients with OG cancer.
3.5.2. Geriatric oncology
Older patients are heterogeneous, with large variations in remaining
life expectancy and vulnerability, and age alone should not guide the
treatment of OG cancer. Comorbidity, which is frequently present, is an
important prognostic factor (Koppert et al., 2012). In patients with SCC,
many patients suﬀer from chronic obstructive pulmonary disease
(COPD), while patients with AdC often have cardiopulmonary co-
morbidities. In addition, weight loss, malnutrition, frailty, sarcopenia
and cognitive impairment are predictors of treatment complications
(see these studies for examples) (Pujara et al., 2015; Chen et al., 2016).
It is important to identify patients who are frail; i.e. patients who are
vulnerable to treatment complications, functional decline and poor
survival (Rostoft, 2017). If the screening is positive, patients need a
broader geriatric assessment which is more comprehensive and also
includes emotional status, polypharmacy and social support. A discus-
sion about goals of care is also necessary. Undergoing a geriatric as-
sessment changes the treatment plan in 39% of older adults with
cancer, in most cases to less aggressive treatment regimens (Hamaker
et al., 2014).
An additional consideration is that certain side-eﬀects of cancer
treatment, such as neuropathy from chemotherapy, can be debilitating
and could push the patient from living in his/her own home to needing
institutional care. A majority of older adults are not willing to trade
living independently for life prolongation (Fried et al., 2002).
Essential requirements
• All older patients (70+) and patients who appear frail or have se-
vere comorbidity must be screened with a quick, simple frailty
screening tool, such as the adapted Geriatric-8 (G8) screening tool
(Petit-Monéger et al., 2016) combined with measurement of 4m gait
speed (Clegg Rogers and Young, 2015).
• Frail patients must undergo a geriatric assessment (Wildiers et al.,
2014). The assessment can be based on self-report combined with
objective assessments that can be performed by a specialist nurse in
collaboration with a physician (geriatrician/specialist in internal
medicine).
• Cognitive impairment aﬀects all aspects of treatment – ability to
consent, compliance with treatment, and risk of delirium – and
screening using tools such as Mini-Cog (Borson et al., 2003) is es-
sential. A geriatrician or a geriatric psychiatrist or neurologist would
preferably be involved, depending on local resources and traditions.
• In frail patients, the geriatrician must be present in the MDT
meeting to discuss treatment options aligned with the patient’s goals
of care.
3.5.3. Oncology pharmacy
Oncology pharmacy plays a critical role in the care of OG cancer,
given the importance of systemic treatment and palliative care. Most
patients will receive drug treatment, mostly chemotherapy, either in
the perioperative setting (stages IB–III) as well as in the metastatic
setting.
The role of the oncology pharmacist is to:
• Liaise with the medical oncologist to discuss pharmaceutical treat-
ment regarding drug administration and patient-individualised
changes in pharmacokinetics. In particular, drug administration into
feeding tubes such as naso-gastric and PEG tubes is often used in
patients with OG cancer
• Counsel patient about taking their drug treatment
• Supervise the preparation of oncology drugs.
Essential requirements
• Oncology pharmacists must be available to advise medical oncolo-
gists on complex pharmacological treatment of patients with OG
cancer owing to common comorbidities and polypharmacy of pa-
tients and the higher risk of drug–drug interactions, changed kidney
and liver function, and interaction with complementary medicines
(e.g. herbal drugs).
• Oncology pharmacists must counsel patients on the correct way to
take treatments such as oral oncology drugs.
• Oncology pharmacists must comply with the European QuapoS
guidelines (European Society of Oncology Pharmacy, 2014). On-
cology drugs must be prepared in the pharmacy and dispensing must
take place under the supervision of the oncology pharmacist.
3.5.4. Psycho-oncology
The prevalence and character of psychological distress in OG and
gastrointestinal cancer patients have been reported in a few studies. For
example, distress is common in patients with all stages of gastric cancer
and is associated with worse outcomes (Kim et al., 2017). In gastro-
intestinal cancer patients, scores of 47.2% and 57% in anxiety and
depression have been reported (Tavoli et al., 2007). Only minor
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changes in anxiety and depression before and after surgery have been
reported through the ﬁrst year after surgery in this patient population,
because of the persistence of symptom burden before diagnosis. Anxiety
is more common in younger patients and depression in those who ex-
perience long-term hospitalisation.
The role of the psycho-oncologist is to:
• Ensure that psychosocial distress, psychological disorders and psy-
chosocial needs are identiﬁed by screening and are considered by
the MDT
• Promote eﬀective communication between patients, family mem-
bers and healthcare professionals especially before surgery and
treatment relating to the consequences of lifestyle aspects (nutrition,
smoking, exercise, uncertainty of prognosis)
• Support patients and family members in coping with multifaceted
disease eﬀects at all stages
• Evaluate psychosocial care programmes.
See also ‘Rehabilitation and survivorship’ and health-related quality
of life issues.
Essential requirements
• Screening for distress using a ‘distress thermometer’ must be carried
out to identify patients with speciﬁc needs.
• Psychological interventions must be provided to all patients with
OG cancer prior to surgery, during treatment and afterwards,
especially to those who are identiﬁed as highly distressed.
• Interventions must include educative and cognitive–behavioural
interventions to: reduce psychological distress and improve taking
care of oneself; empower patients in lifestyle changes; deal with
limitations caused by the disease and treatment; cope with survi-
vorship issues such as return to work, and family and social in-
volvement.
3.5.5. Physiotherapy
Physiotherapists play a particularly important role in the manage-
ment of patients with OG cancer. Many patients have signiﬁcant re-
spiratory comorbidity and reduced levels of physical ﬁtness which can
adversely aﬀect their outcome particularly after major surgery.
Physiotherapists are key to preoperative assessment but also in advising
on preoperative exercise regimes. Their postoperative role in early
mobilisation and respiratory intervention is part of the care pathway for
all patients (Silva et al., 2013).
Essential requirements
• Qualiﬁed physiotherapists must be part of the initial clinical as-
sessment of all patients planned for OG cancer surgery to identify a
patient’s level of physical ﬁtness and provide advice about physical
activity including individual exercise programmes.
• There must be at least daily review of patients after surgery to assist
with early mobilisation until the patient is independently mobile.
• All postoperative patients must be carefully evaluated to determine
their needs for respiratory physiotherapy and appropriate inter-
vention must be available at all times (24/7).
3.5.6. Rehabilitation and survivorship
Survivorship, rehabilitation and supportive care are major issues for
OG cancer patients and are increasing in importance not only as the
number beneﬁting from curative treatment rises but also as the number
of responders to advanced disease treatments increases. Some patients
experience long-term problems related to their primary treatments such
as diﬃculties with eating, nutritional deﬁciencies and disorders of di-
gestion and bowel function.
A few studies have looked at health-related quality of life (HRQL) in
OG patients (Conroy et al., 2006; Derogar and Lagergren, 2012; Schandl
et al., 2016). Trouble with eating, sleeping, talking and fatigue are
common side-eﬀects, especially in the initial period after surgery and
treatment. Nutritional problems and weight loss can make family
members distressed, as in most cultures eating is an essential sign of
wellbeing and a unifying family ritual. Information about these issues
must be communicated to patients and families to enable them to cope.
In general, late-eﬀects from treatments and how patients’ lives are
aﬀected are not well understood. Cancer rehabilitation is crucial in
helping people adapt to their condition and maximise function, in-
dependence and quality of life (Stubbleﬁeld et al., 2013; Ber et al.,
2014; Scott et al., 2013).
Essential requirements
• A multidisciplinary team involving clinicians, nurses, dietitians,
psychologists and physiotherapists must discuss with patients and
their carers the possible long-term eﬀects of cancer treatment and
the types of help available for them, i.e. nutritional support in-
cluding management of disorders of digestion and physical activity.
• Rehabilitation and survivorship must be integrated into care path-
ways to ensure the best possible care continues beyond treatment.
• Professionals must use a person-centred, goal-setting approach,
empowering the patient and their carers to take control of their
rehabilitation.
• Rehabilitation and survivorship must be integrated into national
cancer plans and must include policies concerning welfare, em-
ployment and ﬁnancial services.
4. Other essential requirements
4.1. Patient involvement, access to information and transparency
Patients must be involved in every step of the decision-making
process. Their satisfaction with their care must be assessed throughout
patient care pathways. It is also essential that patient support organi-
sations are involved whenever relevant. Patients must be oﬀered in-
formation to help them understand the treatment process from the
point of diagnosis. They must be supported and encouraged to engage
with their health team to ask questions and obtain feedback on their
treatment wherever possible.
Currently there are few dedicated patient groups for OG cancers in
Europe, but many groups that cover all cancers. Among the dedicated
groups in Europe:
• In 2015, the pan-European group EuropaColon (europacolon.com)
extended its remit to all digestive cancers and will be expanding
support services for OG patients
• The UK has the Oesophageal Patients Association (opa.org.uk),
which was established in 1985, and has an example care pathway on
its site; and also the Barrett’s Oesophagus Campaign (sites.google.
com/site/barrettsoesophaguscampaign), which supports the UK
National Barrett’s Registry (UKBOR). Macmillan has active online
groups for most cancers (https://community.macmillan.org.uk/
groups)
• An Italian stomach cancer group is Vivere Senza Stomaco (viver-
esenzastomaco.org)
• A group in Germany is Ratgeber Magenkrebs Speiseröhrenkrebs
(https://ratgeber-magenkrebs-speiseroehrenkrebs.de).
The European Society for Medical Oncology (ESMO) has patient
guides on oesophageal and stomach cancers available in a number of
languages (http://www.esmo.org/Patients/Patient-Guides) and also a
patient guide on survivorship (http://www.esmo.org/Patients/Patient-
Guides/Patient-Guide-on-Survivorship) produced with the European
Cancer Patient Coalition (ECPC, http://www.ecpc.org).
Conclusions on each MDT case discussion must be made available to
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patients and their primary care physician. Advice on seeking second
opinions must be supported.
Cancer healthcare providers must publish on a website, or make
available to patients on request (such as by providing oﬃcial audit
reports), data on centre/unit performance, including:
• Information services they oﬀer
• Waiting times to ﬁrst appointment
• Pathways of cancer care
• Numbers of patients and treatments at the centre
• Clinical outcomes
• Patient experience measurements (PREMs)
• Incidents/adverse events
• Clinical trials.
4.2. Performance and quality
The ERQCC expert group recommends that OG cancer centres de-
velop:
• Performance measurement metrics/quality indicators based on the
essential requirements in this paper
• Operational policies to ensure the full beneﬁts of a coordinated
clinical pathway based on published guidelines
• Accountability within the governance processes in individual in-
stitutions
• Systems to ensure safe and high-quality patient care and experience
throughout the clinical pathway
• Eﬀective data management and reporting systems
• Engagement with patients, their carers and support groups to ensure
reporting of patient outcomes and experience.
To fully assess the quality of OG cancer care, three categories of
outcomes must be measured and collected in databases at the OG
centre, regionally and/or nationally:
• Clinical outcomes
• Process outcomes
• Patient-reported outcomes (PROs) – in accordance with developing
standards.
This includes national audits where available and national cancer
registration/certiﬁcation.
These approaches can be developed in the context of quality man-
agement systems (QMS) depending on the health economy of an in-
dividual country. The beneﬁts of such a system include:
• Improving processes to enhance patient safety
• Setting standards within a clinical pathway
• Ensuring appropriate resource management including workforce
and ﬁnancial resources
• Facilitating training opportunities
• Determining optimal outcomes with appropriate audit
• Establishing quality of life of patients following treatment.
4.2.1. Audit of outcomes
Data measured and collected varies among countries but it is re-
commended that these outcome metrics are systematically measured
and collected for audit:
• % of preoperative patients discussed in the MDT
• % of postoperative patients discussed in the MDT
• Proportion of patients according to clinical stage at time of diagnosis
• Proportion of patients receiving treatment with curative and pal-
liative intent
• Number of curative procedures
• Complications
• In-hospital mortality
• 1 and 5 year overall survival rate
• Adherence to MDT recommendations.
4.2.2. Multidisciplinary team performance
• All MDT decisions must be documented in an understandable and
timely manner, and must become part of patient records. Decisions
taken during MDT meetings must be monitored, and deviations re-
ported back to the MDT. It is essential that all relevant patient data,
such as pathology reports, meet quality standards and are available
at the time of the MDT meeting.
• The core and extended MDTs must meet at least twice a year to
review the activity of the previous period based on the audited
metrics, discuss changes in protocols and procedures, and improve
the performance of the unit/centre. MDT performance must be
quality assured both internally and by external review with de-
monstration of cost-eﬀectives of quality improvements, and MDT
guidance must be promoted nationally and written into national
cancer plans.
• The ERQCC expert group strongly recommends that further atten-
tion must be given to measures of PROs, not only to agree which
tools should be used, but also to use PROs more systematically as
part of discussions and evaluation within the MDT.
4.2.3. Accreditation
The ERQCC expert group strongly recommends participation in
national or international accreditation programmes, e.g. Organisation
of European Cancer Institutes (OECI) accreditation (http://oeci.
selfassessment.nu/cms) (Wind et al., 2016) and European Cancer Cen-
tres (https://www.krebsgesellschaft.de/gcs/european-cancer-centres.
html).
The ESMO Designated Centres of Integrated Oncology and Palliative
Care accreditation programme started in 2003, under which cancer
centres can receive special recognition for achieving a high standard of
integration of medical oncology and palliative care. This initiative is
particular relevant to the high rate of incurable cases of OG cancer
(http://www.esmo.org/Patients/Designated-Centres-of-Integrated-
Oncology-and-Palliative-Care).
4.2.4. National examples
Listed below are several national quality and audit resources.
• The National Oesophago-Gastric Cancer Audit for the NHS in the
UK, which began in 2006, covers the quality of care given to pa-
tients with OG cancer and oesophageal high-grade dysplasia. It is
based on nationally developed clinical guidelines (Allum et al.,
2011). The report on the year 2016 ﬂags up two concerns: a sig-
niﬁcant proportion of patients with high-grade dysplasia is managed
by surveillance alone instead of endoscopic or surgical treatments as
recommended; and there is variation in care in terms of routes to
diagnosis, the reported use of staging investigations, and proportion
of patients managed with curative intent (NHS, 2016).
• A report on the reorganisation of OG cancer networks in England
and Wales under the national cancer plan reform found that cen-
tralisation of surgery had improved, as had specialist nutritional
support, but the involvement of palliative care in MDTs was lacking
in 20% of hospitals. A paper on the survey provides detailed in-
formation on MDT working and questions asked about access to
procedures and expertise (Groene et al., 2014).
• Germany has a voluntary certiﬁcation system that covers the ma-
jority of cancers, set up by the German Cancer Society (http://www.
ecc-cert.org). The system has been adopted by the German National
Cancer Plan. Certiﬁed cancer centres include those that qualify as a
multidisciplinary gastric cancer centre. The certiﬁcation of gastric
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cancer centres started in 2014: there are currently 28 certiﬁed
centres in Germany and 1 in Switzerland. Certiﬁcation is based on
the current S3 guideline for gastric cancer (Moehler et al., 2011) and
there is a catalogue of structural and quality criteria that must be
fulﬁlled by a site to obtain and maintain the certiﬁcate – e.g. centres
have to treat at least 30 new surgical cases per year. Treatment
decisions must be taken by a MDT, and there are quality indicators.
The centres are audited annually by independent experts and the
results published in a benchmark report. Certiﬁcation of oesopha-
geal cancer centres is planned, based on the S3 guideline.
• The Dutch Upper Gastrointestinal Audit (DUCA) started in 2011 and
provides surgical teams with benchmarked information on process
and outcome measures. A paper reporting early outcomes from the
project shows a signiﬁcant increase in the percentage of oesophageal
cancer patients starting treatment within 5 weeks of diagnosis, and
an increase in the percentage of patients with at least 15 examined
lymph nodes in both oesophageal and gastric cancers (Busweiler
et al., 2016). However, a recent paper found that a ‘textbook out-
come’ for patients included in the audit was achieved in only about
30% of patients with oesophageal cancer and 32% of those with
gastric cancer. The outcome parameter, ‘at least 15 lymph nodes
examined’, had the greatest negative impact (Busweiler et al.,
2017).
• Belgium’s Healthcare Knowledge Centre (KCE) has published quality
indicators for managing OG cancers to support clinical guidelines
and recommendations for centralising care (services have been
widely dispersed in Belgium) (Vlayen et al., 2013). Following as-
sessment, a ﬁnal list of 15 quality indicators for oesophageal cancer
and 14 quality indicators for gastric cancer was drawn up. KCE notes
that according to Avedis Donabedian’s classiﬁcation, quality in-
dicators are categorised by process (what is actually done in giving
and receiving care), outcome (states of health or events that follow
care, and that may be aﬀected by healthcare) and structure (char-
acteristics of providers and the healthcare system that aﬀect the
system’s ability to meet the healthcare needs of individual patients
or a community) (Vlayen et al., 2006). The indicators selected for
Belgium are process and outcome indicators – no structure indicator
was selected. These quality dimensions are covered: eﬀectiveness,
appropriateness, continuity, safety, timeliness and patient-cen-
teredness. No indicator addressed eﬃciency or equity.
4.2.5. The EURECCA project
• At European level, a consortium of cancer societies, including ECCO,
have started a quality improvement programme, European
Registration of Cancer Care (EURECCA), which initially focused on
colorectal cancer. It aims to be a ‘trademark’ for quality assurance in
cancer management in Europe. It has extended its work to other
cancers, including OG (termed upper GI in this project), and has a
number of projects in this category including European comparison
of treatment and outcome of older patients with resectable cancers,
D2 gastrectomy compliance, and international comparison of
treatment.
• The EURECCA upper GI project published a paper in 2016 that
charted variation among 5 countries on curative treatment of OG
cancers based on a common dataset, and was a ‘proof of concept’
that variations and commonalities can be reported in a collaborative
way (Messager et al., 2016b).
• Since then more data has been collected on organisational – not just
surgical – practice in 10 countries, showing for example variations
in the technologies used to stage OG cancers, and that 8 countries
report that all patients are discussed by an MTD but 2 countries –
Italy and Poland – report only 50% and 25% respectively (Messager
et al., 2016a). Treatment is carried out within 1–3 weeks of the MDT
meeting, and mostly in specialist centres, but there are shortcomings
in pre-assessment (for example all countries report carrying out
pulmonary tests but only half do a smoking and alcohol review and
only 4 provide psychological help at this point).
• Only half of the 10 countries have implemented enhanced recovery
after surgery (ERAS) programmes, which are seen as a ‘paradigm
shift’ in perioperative care, ‘resulting in substantial improvements in
clinical outcomes and cost savings’ (Ljungqvist et al., 2017), and are
especially applicable to complex care required for OG cancer
treatment. The ERAS Society has guidelines for aspects of upper GI
surgery (http://erassociety.org).
• Among other variations, specialist nurses are available in only half
of the countries.
5. Cancer education and training
It is essential that each OG cancer centre provides professional
clinical and scientiﬁc education on the disease and that at least one
person is responsible for this programme. Healthcare professionals
working in OG cancer must also receive training in psychosocial on-
cology, palliative care, rehabilitation and communication skills. Such
training must also be incorporated into postgraduate and under-
graduate curricula for physicians, nurses and other professionals.
Collaborative opportunities should be available for trainees from all
professional backgrounds to gain experience by exchange between
countries.
6. Clinical research
• Institutions active in research can achieve better outcomes for the
entire patient group rather than just the research participants (for
example in colorectal cancer) (Downing et al., 2017). Centres
treating OG cancers must have clinical research programmes (either
their own research or as a participant in programmes led by other
centres). The MDT must assess all new patients for eligibility to take
part in academic and industry sponsored clinical trials at the centre
or in research networks. Collaboration with European academic
networks is strongly recommended – see the European Organisation
for Research and Treatment of Cancer (EORTC – http://www.eortc.
org) and the European Clinical Research Infrastructure Network
(ECRIN – http://www.ecrin.org).
• EURECCA’s upper GI project asked about surgical academic work in
its 10-country survey, ﬁnding wide variation in patients screened for
clinical trial participation and those included, with Denmark having
the highest percentage of both patients screened and included in
studies.
• Clinical trial enrolment for OG cancers can be diﬃcult owing to
moderate to low incidence. Collaboration between high volume
centres and community hospitals is needed to identify patients for
clinical trials. Innovative study designs can be explored to develop
more eﬃcient and targeted clinical trials that will detect large dif-
ferences (Lin and He, 2015).
• Correlative biomarker research is a crucial part of all phases of
clinical studies, and requires close cooperation among clinicians,
especially surgical and pathology teams, and with biologists and
biobanks within research networks such as EORTC’s SPECTA pro-
gramme (http://www.eortc.org/other-research-initiatives/specta).
• Patient-reported outcomes, especially concerning quality of life,
must be included as endpoints in clinical trials. This is of particular
importance for OG cancers, as they have a high incidence of disease-
related symptoms but also a high incidence of treatment-associated
morbidity.
• For OG cancers, centres should have at least 5% of all patients in-
cluded in clinical research. Members of the research teams (clin-
icians, scientists or nurses) from other centres should be considered
as part of the extended MDT for at least a bi-annual discussion of
clinical trial participation. Older adults, in particular frail older
adults, are currently underrepresented in cancer clinical trials
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despite having a disproportionate burden of disease (Kaźmierska,
2013). Strategies to increase the participation of older adults in
clinical trials must be implemented and trials designed to take into
account their needs (Wildiers et al., 2013).
• FREGAT (French EsoGastric Tumours – https://www.fregat-
database.org) is a good example of a national clinic-biological pro-
spective database that is collecting data and samples from patients
with OG cancers in France. It will include data on access to care and
quality of life.
7. Conclusion
Taken together, the information presented in this paper provides a
comprehensive description of the essential requirements for estab-
lishing a high-quality OG cancer service. The ERQCC expert group is
aware that it is not possible to propose a ‘one size ﬁts all’ system for all
countries, but urges that access to multidisciplinary units or centres
must be guaranteed for all those with OG cancers.
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